Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $92.1 million.

  • Abivax's Total Current Liabilities changed N/A to $92.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.1 million, marking a year-over-year change of. This contributed to the annual value of $100.4 million for FY2024, which is 238.57% up from last year.
  • Latest data reveals that Abivax reported Total Current Liabilities of $92.1 million as of Q3 2025.
  • Abivax's Total Current Liabilities' 5-year high stood at $127.2 million during Q2 2025, with a 5-year trough of $36.9 million in Q4 2021.
  • For the 5-year period, Abivax's Total Current Liabilities averaged around $88.0 million, with its median value being $94.8 million (2023).
  • As far as peak fluctuations go, Abivax's Total Current Liabilities skyrocketed by 8584.99% in 2023, and later soared by 293.55% in 2024.
  • Over the past 5 years, Abivax's Total Current Liabilities (Quarter) stood at $36.9 million in 2021, then surged by 42.25% to $52.5 million in 2022, then surged by 85.85% to $97.6 million in 2023, then grew by 2.94% to $100.4 million in 2024, then decreased by 8.33% to $92.1 million in 2025.
  • Its Total Current Liabilities was $92.1 million in Q3 2025, compared to $127.2 million in Q2 2025 and $111.2 million in Q1 2025.